Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469562 | 0.91 | TLR7 (0.44) | TLR7MAPK1ALDH1A1GAA | |
| SCHEMBL5462434 | 0.89 | MAPK1 (0.39) | TLR7MAPK1ADORA3ADORA1 | |
| SCHEMBL5459732 | 0.88 | TLR7 (0.45) | TLR7MAPK1ALDH1A1GAA | |
| SCHEMBL5464413 | 0.86 | MAPK1 (0.40) | TLR7MAPK1ADORA3ADORA1 | |
| SCHEMBL2060058 | 0.84 | TLR7 (0.45) | TLR7MAPK1KDM4EALDH1A1GLA | |
| SCHEMBL5458033 | 0.83 | TLR7 (0.51) | TLR7 | |
| SCHEMBL2060356 | 0.82 | MAPK1 (0.45) | TLR7MAPK1ADORA3ALDH1A1GAA | |
| SCHEMBL5467077 | 0.82 | TLR7 (0.50) | TLR7KDM4EALDH1A1GLAGAA | |
| SCHEMBL7208584 | 0.81 | MAPK1 (0.47) | TLR7MAPK1ADORA3TSHRADORA1 | |
| SCHEMBL5468687 | 0.80 | TLR7 (0.62) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | claimed |
| EP-1728792-A1 | 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | claimed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1728792-A1 | 8-OXOADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | TLR7 1/4885MAPK1 2737/4885ADORA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.